Yahoo Web Search

  • FirefoxTry Yahoo Search on Firefox »
    1. Sort by

    1. HACKENSACK, N.J. and PETACH TIKVAH, Israel, April 14, 2015 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, ...

    2. NEW YORK (TheStreet) -- Brainstorm Cell Therapeutics shares are up 9.13% to $5.02 as the biopharmaceutical company's stock gains momentum after the company announced that it will present positive results from its phase 2a study of NurOwn when it releases the full set of data next week at the American Academy of Neurology annual meeting. The Israel-based developer of adult stem cell technologies...

    3. Press Release

      PharmiWebApr 14 5:30 AM

      HACKENSACK N.J. and PETACH TIKVAH Israel April 14 2015 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) a leading developer of adult stem cell technologies for neurodegenerative diseases today announced that results from its phase 2a study of NurOwn® in amyotrophic lateral sclerosis (ALS) and additional analyses will be presented at the American Academy of Neurology annual ...

    4. Shares of small-cap Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI ) spiked more than 6 percent Friday morning after prominent neurosurgeon Dr. Sanjay Gupta tweeted there is now a "ray of hope" ...

    5. HACKENSACK, N.J. and PETACH TIKVAH, Israel, March 19, 2015 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, ...

    6. BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results for the three months and year ended December 31, 2014.

    7. HACKENSACK, N.J. and PETACH TIKVAH, Israel, March 26, 2015 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, ...

    8. BrainStorm Cell Therapeutics ( BCLI -1.6% ) Q4 results : Revenues: $0; R&D Expense: $1.6M (+100.0%); SG&A: $1M (+100.0%); Operating Loss: ($2.7M) (-92.9%); Net Loss: ($2.7M) (-125.0%); Loss Per Share: ($0.18) (-80.0%).

    9. BrainStorm Cell Therapeutics (NASDAQ: BCLI ): Q4 EPS of -$0.18 misses by $0.03 . Sent to 1,428 people who get email alerts on BCLI.

    10. Mark Yusko was recently a weekly guest on #PreMarket Prep , a daily trading idea radio show hosted by Joel Elconin and Dennis Dick.. Yusko is the Founder and Chief Investment Officer of Morgan Creek Capital. ...

    1. 1212 results